Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)

NCT07099898 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07099898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07099898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Recruiting
Start date
August 11, 2025
Completion date
September 28, 2029
Enrollment
420 (estimated)
Sites
135

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, lung